Article
Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study.
JAMA psychiatry - 1 Mar 2015
Pietrzak Robert H, Lim Yen Ying, Neumeister Alexander, Ames David, Ellis Kathryn A, Harrington Karra, Lautenschlager Nicola T, Restrepo Carolina, Martins Ralph N, Masters Colin L, Villemagne Victor L, Rowe Christopher C, Maruff Paul
Abstract excerpt
IMPORTANCE: Alzheimer disease (AD) is now known to have a long preclinical phase in which pathophysiologic processes develop many years, even decades, before the onset of clinical symptoms. Although the presence of abnormal levels of amyloid-β (Aβ) is associated with higher rates of progression to clinically classified mild cognitive impairment or dementia, little research has evaluated potentially modifiable...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.